Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hikma PharmaceuticalsHKMPF +3.33%81 EV-to-EBITDA is 7.66 as of Aug. 08, 2026, which is 34% below its 10-year median of 11.53. GuruFocus rates HKMPF with a GF Score™ of 81/100 and a GF Value™ of $27.72 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 739 Drug Manufacturers companies, Hikma Pharmaceuticals ranks better than 73.07% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Hikma Pharmaceuticals's enterprise value is $6,622 Mil.
Hikma Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $864 Mil. Therefore, Hikma Pharmaceuticals's EV-to-EBITDA for today is 7.66.
The historical rank and industry rank for Hikma Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
HKMPF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.54 Med: 11.53 Max: 17.41
Current: 7.66
During the past 13 years, the highest EV-to-EBITDA of Hikma Pharmaceuticals was 17.41. The lowest was 5.54. And the median was 11.53.
HKMPF's EV-to-EBITDA is ranked better than 73.07% of 739
companies
in the Drug Manufacturers industry
Industry Median: 13.37
vs HKMPF: 7.66
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Hikma Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Hikma Pharmaceuticals's share price for today is $22.2775.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Hikma Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was $1.760.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Hikma Pharmaceuticals EV-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Hikma Pharmaceuticals's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Hikma Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hikma Pharmaceuticals EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hikma Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Hikma Pharmaceuticals's EV-to-EBITDA falls into.
Hikma Pharmaceuticals's current Enterprise Value is $6,622 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Hikma Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $864 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hikma Pharmaceuticals (HKMPF) has a EV-to-EBITDA of 7.66 as of Aug. 08, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Hikma Pharmaceuticals. This is 34% below median its historical median of 11.53. Over the past decade, Hikma Pharmaceuticals' EV-to-EBITDA has ranged from 5.54 to 17.41. According to the industry distribution chart, Hikma Pharmaceuticals ranks #199 out of 739 companies in the Drug Manufacturers industry, placing it in the top 26.9%.
Is Hikma Pharmaceuticals' EV-to-EBITDA too high?
Hikma Pharmaceuticals' current EV-to-EBITDA of 7.66 is 34% below median its 10-year median of 11.53. Over the past 10 years, this metric has ranged from a low of 5.54 to a high of 17.41. The Drug Manufacturers industry median EV-to-EBITDA is 13.37. Hikma Pharmaceuticals' value of 7.66 is 42.7% below this industry median. Based on the distribution chart, Hikma Pharmaceuticals ranks #199 out of 739 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Hikma Pharmaceuticals has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hikma Pharmaceuticals' EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hikma Pharmaceuticals ranks #199 out of 739 companies for EV-to-EBITDA. This puts Hikma Pharmaceuticals in the upper half of its industry. The industry median EV-to-EBITDA is 13.37. Hikma Pharmaceuticals' value of 7.66 is 42.7% below this benchmark. Historically, Hikma Pharmaceuticals' own EV-to-EBITDA has ranged from 5.54 to 17.41 over the past decade. While the company's 10-year median is 11.53 vs. the industry median of 13.37, Hikma Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.37, based on 739 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hikma Pharmaceuticals's current EV-to-EBITDA of 7.66 is 42.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Hikma Pharmaceuticals. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hikma Pharmaceuticals's current EV-to-EBITDA is 7.66, which is 34% below median its own 10-year median of 11.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hikma Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hikma Pharmaceuticals (HKMPF) is currently considered Modestly Undervalued. The stock's GF Value™ is $27.72, compared to a current price of $22.28 — trading 19.6% below its estimated fair value. The current EV-to-EBITDA is 7.66, which is 34% below median its 10-year median of 11.53 and 42.7% below the Drug Manufacturers industry median of 13.37. Hikma Pharmaceuticals' overall GF Score™ is 81/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Hikma Pharmaceuticals (HKMPF), the current EV-to-EBITDA is 7.66 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hikma Pharmaceuticals (HKMPF) Overvalued in 2026?
Based on GuruFocus' analysis, Hikma Pharmaceuticals stock appears to be undervalued.
The current stock price of $22.28 is trading 19.6% below its estimated GF Value™ of $27.72.
GuruFocus considers Hikma Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for HKMPF:
EV-to-EBITDA: 7.66 (34% below median its 10-year median of 11.53)
GF Value™: $27.72 vs. price of $22.28 (19.6% below fair value)
Industry Position: 42.7% below the Drug Manufacturers median (#199 of 739)
No single metric tells the full story. See the HKMPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
81GF Score
Get the complete analysis for HKMPF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKMPF has been successfully added to your 
